CEL-SCI (NYSE:CVM) and MiNK Therapeutics (NASDAQ:INKT) Head-To-Head Contrast

MiNK Therapeutics (NASDAQ:INKT) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares MiNK Therapeutics and CEL-SCI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-265.44%
CEL-SCI	N/A	-218.00%	-98.53%

Earnings & Valuation

This table compares MiNK Therapeutics and CEL-SCI’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.60)	-1.41
CEL-SCI	N/A	N/A	-$32.19 million	($0.63)	-1.87

CEL-SCI is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MiNK Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 17.8% of MiNK Therapeutics shares are held by insiders. Comparatively, 16.2% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for MiNK Therapeutics and CEL-SCI, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	1	0	3.00
CEL-SCI	0	0	0	0	N/A

MiNK Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 960.57%. Given MiNK Therapeutics’ higher possible upside, equities analysts plainly believe MiNK Therapeutics is more favorable than CEL-SCI.

Summary

MiNK Therapeutics beats CEL-SCI on 7 of the 10 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.